In this week's issued patents, GW Pharmaceuticals was the recipient of 3 new patents (US Pats. 10,709,671, 10,709,673, & 10,709,674), all related to the treatment of epilepsy using CBD.
Patent ‘671 teaches how to use cannabinoids, specifically CBD, to treat focal seizures in children and young adults suffering from Dravet’s syndrome. Focal seizures are seizures that originate in one part of the brain and can potentially spread to other parts of the brain. Physicians categorize simple focal seizures into four types: Motor, Sensory, Autonomic and Psychic (Johns Hopkins). A high purity CBD composition containing anti-epileptic drugs and low amounts of cannabidivarin (CBDV) were suggested to be effective at reducing focal seizures in patients with treatment-resistant Dravet’s syndrome. Similarly, patents ‘763 and ‘764 disclose a way to treat atonic seizures using a high purity CBD composition. Atonic seizures are a type of seizure that cause loss of muscle strength.
GW’s Epidiolex has made waves in the cannabis and pharmaceutical industry, with sales reaching an incredible $296 million at the end of their launch year in 2019 (CNBC). GW Pharmaceuticals remains the top dog in the industry with over 180 cannabis-related patents and patent applications spanning nearly all 12 categories in the Magic Number Cannabis Patent Forecast®. Stay ahead of your competition with a subscription to Magic Number!
